ImmuneOncia Therapeutics
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
ImmuneOncia Therapeutics develops antibody-based cancer immunotherapy drugs, medicines that help the immune system recognize and attack tumors.
It holds a pipeline of monoclonal antibodies (highly targeted proteins engineered to block specific cancer-promoting signals) as its core assets. Listed on KOSDAQ, Korea's tech-focused small-cap exchange, the company operates primarily as a drug-licensing business: it advances candidate therapies through early clinical trials, then transfers the technology to partners in exchange for licensing fees, while also pursuing domestic commercialization of its lead antibody.
Summary is AI-generated and may contain errors · figures from DART filings
ImmuneOncia Therapeutics in five facts
What does ImmuneOncia Therapeutics do?
ImmuneOncia Therapeutics develops antibody-based cancer immunotherapy drugs, medicines that help the immune system recognize and attack tumors.
Where is ImmuneOncia Therapeutics listed and in which sector?
ImmuneOncia Therapeutics (Korean name: 이뮨온시아) trades under KRX code 424870 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is ImmuneOncia Therapeutics?
Its market capitalisation was US$213.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were ImmuneOncia Therapeutics's latest annual revenue and operating profit?
For fiscal year 2025, ImmuneOncia Therapeutics reported revenue of US$83.9K, an operating loss of US$21.1M and a net loss of US$20.7M, per its annual report on DART (data retrieved from DART on 2026-06-04).
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-04
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Investor relations (IR) meetingOct 15
- Material management matter relevant to investment decisionsSep 14
- Material management matter relevant to investment decisionsSep 14
- Subscription results of rights offering or equity-linked bonds (voluntary)Capital raise · May 15
- [Amended] Material event report (rights offering)
ImmuneOncia Therapeutics updated the terms of a new share issuance to raise US$71.5M, about 33.1% of its market value.
Capital raise · May 11 · 4 versions - Rights offering: final issue price setCapital raise · May 8
- Ex-rights (rights offering)Capital raise · Apr 2
- Rights offering: round 1 issue price setCapital raise · Apr 2
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
ImmuneOncia Therapeutics reported separate results for FY2025: revenue of US$75.6K (−83% year on year), an operating loss of US$19.2M and a net loss of US$18.8M.
Earnings · Feb 6